Mucosolvan Mini (Ambroxol Hydrochloride)

Ambroxol Hydrochloride stimulates surfactant production by type II pneumocytes and breaks down mucus glycoproteins, reducing the viscosity and elasticity of secretions. This enhances mucociliary clearance, allowing mucus to be transported toward the throat and expelled more readily during coughing.

The appropriate dose of Mucosolvan Mini is determined by a qualified prescriber based on the patient’s age, weight, clinical condition, and local prescribing guidelines. Patients should follow the specific instructions provided by their healthcare professional and the product label.

Safety data for Ambroxol Hydrochloride in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Compared with acetylcysteine, another common mucolytic, Ambroxol Hydrochloride has a dual action: it not only thins mucus but also stimulates surfactant secretion, which may improve cough efficiency. Both agents are OTC, but Ambroxol is often preferred for its additional anti‑inflammatory properties.

Mucosolvan Mini should be stored at room temperature below 25 °C, in the original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid storing in damp or excessively hot environments to maintain stability.

Mucosolvan Mini is taken orally. The tablet (or oral formulation) should be swallowed whole with a glass of water, preferably after meals to reduce gastrointestinal discomfort. Patients should not crush or chew the tablet unless specifically instructed by a healthcare professional.

Serious adverse reactions, although rare, include allergic responses such as urticaria, angioedema, or anaphylaxis, as well as severe skin conditions like Stevens‑Johnson syndrome and hepatic dysfunction. Any signs of these reactions require immediate medical attention and discontinuation of the product.

Mucosolvan Mini should be avoided in individuals with known hypersensitivity to Ambroxol Hydrochloride or any excipients in the formulation. Caution is advised for patients with severe hepatic impairment, and it is not recommended for use in children below the age specified by local regulatory guidance.